The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,002
Barroso‐Sousa, R., & Ott, P. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0738-2 · Cited by 24
Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy
Kishton, R. J., Lynn, R. C., & Restifo, N. P. (2020) · Cell · doi:10.1016/j.cell.2020.10.011 · Cited by 24
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy
Li, Q., Ngo, P., & Egilmez, N. K. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02795-2 · Cited by 24
Muscarella, P., Bekaii-Saab, T., McIntyre, K., Rosemurgy, A., Ross, S. B., Richards, D. A., Fisher, W. E., Flynn, P. J., Mattson, A., Coeshott, C., et al. (2021) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0021 · Cited by 24
Zhang, F., Yuan, D., Song, J., Chen, W., Wang, W., Zhu, G., Hu, B., Chen, X., & Zhu, J. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107899 · Cited by 24
Antigen‐specific and cross‐reactive T cells in protection and disease
Jiang, N. J., Malone, M. D., & Chizari, S. (2023) · Immunological Reviews · doi:10.1111/imr.13217 · Cited by 25
Li, C. M. Y., Li, R., Drew, P. A., Price, T. J., Smith, E., Maddern, G. J., Tomita, Y., & Fenix, K. A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102665 · Cited by 25
Discovery of U2AF1 neoantigens in myeloid neoplasms
Biernacki, M. A., Lok, J., Black, R. G., Foster, K. A., Cummings, C. C., Woodward, K. B., Monahan, T. M., Oehler, V. G., Stirewalt, D. L., Wu, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007490 · Cited by 24
Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen
Zhang, M., Xu, W. L., Luo, L., Guan, F., Wang, X., Zhu, P., Zhang, J., Zhou, X., Wang, F., & Ye, S. (2024) · Communications Biology · doi:10.1038/s42003-024-06209-2 · Cited by 24
The Heterocellular Emergence of Colorectal Cancer
Tape, C. J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.12.004 · Cited by 24
Miller, M. S., Douglass, J., Hwang, M. S., Skora, A. D., Murphy, M. B., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Zhou, S., & Gabelli, S. B. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010251 · Cited by 24
Recent research progress and clinical status of immunotherapy for colorectal cancer
Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 27
TCR gene-engineered cell therapy for solid tumors
Tan, E. S., Gakhar, N., & Kirtane, K. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101285 · Cited by 23
T cell receptors employ diverse strategies to target a p53 cancer neoantigen
Wu, D., Gowathaman, R., Pierce, B. G., & Mariuzza, R. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101684 · Cited by 26
Minegishi, Y., Kiyotani, K., Nemoto, K., Inoue, Y., Haga, Y., Fujii, R., Saichi, N., Nagayama, S., & Ueda, K. (2022) · Communications Biology · doi:10.1038/s42003-022-03807-w · Cited by 23
Velasteguí, E., Vera, E., Berghe, W. V., Muñoz, M. S., & Orellana‐Manzano, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1206034 · Cited by 23
Zhou, W., Xiang, W., Yu, J., Ruan, Z., Pan, Y., Wang, K., & Liu, J. (2024) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzae010 · Cited by 23
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
Nielsen, J. S., Chang, A., Wick, D. A., Sedgwick, C. G., Zong, Z., Mungall, A. J. J., Martin, S. D., Kinloch, N. N., Ott-Langer, S., Brumme, Z. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1321184 · Cited by 24
Hulett, T. W., Jensen, S. M., Wilmarth, P. A., Reddy, A. P., Ballesteros‐Merino, C., Afentoulis, M. E., Dubay, C., David, L. L., & Fox, B. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0331-0 · Cited by 23
Ushering in Integrated T Cell Repertoire Profiling in Cancer
Jiang, N. J., Schonnesen, A. A., & Ma, K.-Y. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.005 · Cited by 25
Murata, K., Nakatsugawa, M., Rahman, M. A., Nguyen, L. T., Millar, D. G., Mulder, D. T., Sugata, K., Saijo, H., Matsunaga, Y., Kagoya, Y., et al. (2020) · eLife · doi:10.7554/elife.53244 · Cited by 23
Wan, Y., Zhang, Y., Wang, G., Mwangi, P. M., Cai, H., & Li, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01326 · Cited by 24
The Role of Neoantigens in Cancer Immunotherapy
Zhu, Y., & Liu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682325 · Cited by 25
Therapeutic bispecific antibodies against intracellular tumor antigens
Xu, G., Luo, Y., Wang, H., Wang, Y., Liu, B., & Wei, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215699 · Cited by 23
Lymphocytes as a living drug for cancer
Rosenberg, S. A. (2024) · Science · doi:10.1126/science.adp1130 · Cited by 23
Self-citationReticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 23
Pasetto, A., & Lu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689091 · Cited by 24
Self-citationSun, J., Zhang, J., Hu, H., Qin, H., Liao, X., Wang, F., Zhang, W., Yin, Q., Su, X., He, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03735-y · Cited by 22
Synthetic receptors for logic gated T cell recognition and function
Simon, S., Bugos, G., Salter, A. I., & Riddell, S. R. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.09.003 · Cited by 23
Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome
Bolívar, A. M., Düzağaç, F., Sinha, K. M., & Vilar, E. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101204 · Cited by 22
Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Martin, S. D., Bhuiyan, I., Soleimani, M., & Wang, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154987 · Cited by 23
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 24
Hua, S., Gu, X., Jin, H., Zhang, X., Liu, Q., & Yang, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117080 · Cited by 22
Crompton, J. G., Klemen, N. D., & Kammula, U. S. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6266-8 · Cited by 22
Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer
Meng, Q., Valentini, D., Rao, M., Moro, C. F., Paraschoudi, G., Jäger, E., Dodoo, E., Rangelova, E. B., Chiaro, M. D., & Maeurer, M. J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0262-z · Cited by 22
Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas
Zheng, B., Wang, J., Cai, W., Lao, I. W., Shi, Y., Luo, X., & Yan, W. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.43 · Cited by 23
Sällberg, M., & Pasetto, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00552 · Cited by 22
Self-citationHe, S., Tian, S., He, X., Le, X., Ning, Y., Chen, J., Chen, H., Mu, J., Xu, K., Xiang, Q., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.08.008 · Cited by 22
van Asten, S. D., de Groot, R., van Loenen, M. M., Castenmiller, S. M., de Jong, J., Monkhorst, K., Haanen, J. B. A. G., Amsen, D., Bex, A., Spaapen, R. M., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860482 · Cited by 22
Hao, Q., Long, Y., Yang, Y., Deng, Y., Ding, Z., Yang, L., Shu, Y., & Xu, H. (2024) · Vaccines · doi:10.3390/vaccines12070717 · Cited by 22
Kuilman, T., Schrikkema, D. S., Gadiot, J., Gomez, R., Bies, L., Walker, J., Spaapen, R. M., Kok, H., Houg, D., Viyacheva, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55420-6 · Cited by 22
Feng, H., & Shen, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.564796 · Cited by 21
Biomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 21
Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
Zhang, W., Yin, Q., Huang, H., Lu, J., Qin, H., Chen, S., Zhang, W., Su, X., Sun, W., Dong, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628456 · Cited by 21
Matsuki, M., Hirohashi, Y., Nakatsugawa, M., Murai, A., Kubo, T., Hashimoto, S., Tokita, S., Murata, K., Kanaseki, T., Tsukahara, T., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03048-6 · Cited by 21
Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
Alarcon, N. O., Jaramillo, M., Mansour, H. M., & Sun, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071448 · Cited by 21
Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer
Anupriya, S., Chakraborty, A., & Patnaik, S. (2022) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2022.108445 · Cited by 22
Immunotherapy and Pancreatic Cancer: A Lost Challenge?
Laface, C., Memeo, R., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Cazzato, G., Guarini, C., Santis, P. D., et al. (2023) · Life · doi:10.3390/life13071482 · Cited by 22
Dougé, A., El-Ghazzi, N., Lemal, R., & Rouzaire, P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0310 · Cited by 21
IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells
Fesneau, O., Samson, K. A., Rosales, W. K., Jones, B., Moudgil, T. L., Fox, B. A., Rajamanickam, V., & Duhen, T. M. (2024) · Nature Communications · doi:10.1038/s41467-024-54420-w · Cited by 25
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Pant, S., Hubbard, J. M., Martinelli, E., & Bekaii‐Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 21
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21
Etxeberría, I., Olivera, I., Bolaños, E., Cirella, A., Teijeira, Á., Berraondo, P., & Melero, I. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0464-1 · Cited by 23
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
Iafolla, M. A. J., Yang, C., Chandran, V., Pintilie, M., Li, Q., Bedard, P. L., Hansen, A. R., Lheureux, S., Spreafico, A., Razak, A. A., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa115 · Cited by 21
Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy
Zhu, Y., Qian, Y., Li, Z., Li, Y., & Li, B. (2021) · MedComm · doi:10.1002/mco2.41 · Cited by 23
Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
Kinoshita, T., Terai, H., & Yaguchi, T. (2021) · Life · doi:10.3390/life11101029 · Cited by 23
Immunotherapies catering to the unmet medical need of cold colorectal cancer
Yuan, J., Li, J., Gao, C., Jiang, C., Xiang, Z., & Wu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022190 · Cited by 21
Tumor-infiltrating lymphocytes make inroads in non–small-cell lung cancer
Veatch, J. R., Simon, S., & Riddell, S. R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01445-z · Cited by 22
Anderson, G. S. F., & Chapman, M. A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.028 · Cited by 20
Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps
Rodrigo, B. N., Ortiz-Miranda, Y., Corría-Osorio, J., Coukos, G., & Harari, A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.002 · Cited by 22
Manjili, M. H. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2017.11.005 · Cited by 20
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 20
Penny, S. A., Abelin, J. G., Malaker, S. A., Myers, P. T., Saeed, A. Z., Steadman, L. G., Bai, D. L., Ward, S., Shabanowitz, J., Hunt, D. F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723566 · Cited by 20
KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
García-Robledo, J. E., Rosell, R., Ruíz-Patiño, A., Sotelo, C., Arrieta, O. G., Zatarain-Barrón, L., Ordóñez‐Reyes, C., Jaller, E., Rojas, L., Russo, A., et al. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211066064 · Cited by 22
Meraviglia-Crivelli, D., Zheleva, A., Barainka, M., Moreno, B., Villanueva, H., & Pastor, F. (2022) · Biomedicines · doi:10.3390/biomedicines10081842 · Cited by 20
Yu, G., He, X., Li, X., & Wu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113464 · Cited by 20
Chen, J., Chen, J., & Wang, L. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200174 · Cited by 21
Faghfuri, E. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0054 · Cited by 20
Drakes, D. J., Abbas, A. M., Shields, J., Steinbuck, M. P., Jakubowski, A., Seenappa, L. M., Haqq, C. M., & DeMuth, P. C. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0978 · Cited by 20
Cancer research in the era of immunogenomics
Wolf, Y., & Samuels, Y. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000475 · Cited by 20
PD-L1 Expression Affects Neoantigen Presentation
Okada, M., Shimizu, K., Iyoda, T., Ueda, S., Shinga, J., Mochizuki, Y., Watanabe, T., Ohara, O., & Fujii, S. (2020) · iScience · doi:10.1016/j.isci.2020.101238 · Cited by 20
El-Khazragy, N. N., Ghozy, S. A., Emad, P., Mourad, M., Razza, D., Farouk, Y. K., Mohamed, N. A., Ahmed, M. K., Youssef, T., Bahnasawy, Y. M., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0181 · Cited by 20
Industrializing engineered autologous T cells as medicines for solid tumours
Britten, C. M., Shalabi, A. M., & Hoos, A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00175-8 · Cited by 20
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
Dillard, P., Casey, N. P., Pollmann, S., Vernhoff, P., Gaudernack, G., Kvalheim, G., Wälchli, S., & Inderberg, E. M. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1936757 · Cited by 20
Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers
Chen, L., Qiao, D., Wang, J., Tian, G., & Wang, M. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.10.002 · Cited by 21
Fast and accurate modeling of TCR-peptide-MHC complexes using tFold-TCRPreprint
Wu, F., Zhao, Y. S., Xiao, Y., Qin, C., Wang, F., Wu, Z., Huang, L.-K., Liu, X., Song, J., He, B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.12.632367 · Cited by 20
Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
Yao, D., Xu, L., Tan, J., Zhang, Y., Lu, S., Li, M., Lu, S., Yang, L., Chen, S., Chen, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20965 · Cited by 19
Self-citationTumor infiltration therapy: from FDA approval to next-generation approaches
Shaik, R., Royyala, S. A., Inapanuri, B., Durgam, A., Khan, H., & Unnisa, A. Z. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01574-6 · Cited by 20
Boosting Antitumor Immunity with an Expanded Neoepitope Landscape
Nagel, R., Pataskar, A., Champagne, J., & Agami, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1525 · Cited by 21
SpecHLA enables full-resolution HLA typing from sequencing data
Wang, S., Wang, M., Chen, L., Pan, G., Wang, Y., & Li, S. C. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100589 · Cited by 19
Piroozkhah, M., Gholinezhad, Y., Piroozkhah, M., Shams, E., & Mojarad, E. N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298891 · Cited by 21
Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties
Upadhye, A., Landeros, K. E. M., Ramírez-Suástegui, C., Schmiedel, B. J., Woo, E. B. C., Chee, S., Malicki, D. M., Coufal, N. G., Gonda, D. D., Levy, M. L., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00706-9 · Cited by 19
Structural basis for self-discrimination by neoantigen-specific TCRs
Finnigan, J. P., Newman, J. H., Patskovsky, Y., Patskovska, L., Ishizuka, A. S., Lynn, G. M., Seder, R. A., Krogsgaard, M., & Bhardwaj, N. (2024) · Nature Communications · doi:10.1038/s41467-024-46367-9 · Cited by 20
iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma
Ishii, M., Ando, J., Yamazaki, S., Toyota, T., Ohara, K., Furukawa, Y., Suehara, Y., Nakanishi, M., Nakashima, K., Ohshima, K., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0193 · Cited by 19
Marshall, N., Hutchinson, K., Marron, T. U., Aleynick, M., Hammerich, L., Upadhyay, R., Svensson‐Arvelund, J., Brown, B. D., Mérad, M., & Brody, J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0391 · Cited by 19
Intratumoral heterogeneity and immunotherapy resistance: clinical implications
Keenan, B. P., Yadav, M., Ansstas, G., Fabrizio, D. A., Murugesan, K., Montesion, M., Niyogi, D. G., Mellman, I., & Melero, I. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1239 · Cited by 19
Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors
Kimura, Y., Ghosn, M., Cheema, W., Adusumilli, P. S., Solomon, S. B., & Srimathveeralli, G. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.018 · Cited by 18
Smok-Kalwat, J., Mertowska, P., Mertowski, S., Smolak, K., Kozińska, A., Koszałka, F., Kwaśniewski, W. M., Grywalska, E., & Góźdź, S. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021506 · Cited by 21
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma
Schaettler, M. O., Desai, R. R., Wang, A. Z., Livingstone, A. J., Kobayashi, D. K., Coxon, A. T., Bowman-Kirigin, J. A., Liu, C. J., Mao, L., Bender, D. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006121 · Cited by 21
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
Ai, Q., Li, F., Zou, S., Zhang, Z., Jin, Y., Jiang, L., Chen, H., Deng, X., Peng, C., Mou, N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161538 · Cited by 18
Computational design and validation of effective siRNAs to silence oncogenic KRAS
Ramalingam, P. S., & Arumugam, S. (2023) · 3 Biotech · doi:10.1007/s13205-023-03767-w · Cited by 18
Huang, K. C., Ke, T., Lai, C.-Y., Hong, W.-Z., Chang, H.-Y., Lee, C., Wu, C.-H., Chiang, S., Liang, J., Chen, J.-Y., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116958 · Cited by 18
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 19
Faden, D. L., Concha‐Benavente, F., Chakka, A. B., McMichael, E. L., Chandran, U. R., & Ferris, R. L. (2019) · Head & Neck · doi:10.1002/hed.25726 · Cited by 18
Blair, T. C., Alice, A. F., Zebertavage, L., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653625 · Cited by 19
Zhou, S., Liu, S., Zhao, L., & Sun, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.786438 · Cited by 18
Guo, J., Wang, C., Luo, N., Wu, Y., Huang, W., Zhu, J., Shi, W., Ding, J., Ge, Y., Liu, C., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03420-0 · Cited by 17
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma
Creasy, C. A., Meng, Y. J., Forget, M., Karpinets, T. V., Tomczak, K. J., Stewart, C., Torres-Cabala, C. A., Pilon‐Thomas, S., Sarnaik, A. A., Mulé, J. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1060 · Cited by 17
Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
de Sousa, E., Lérias, J. R., Antonio Lopez-beltran, B., Paraschoudi, G., Condeço, C., Kamiki, J., António, P., Figueiredo, N., Carvalho, C. T., Castillo-Martín, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.592031 · Cited by 17
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 18
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
